Healthcare

OncoSil Medical Limited (ASX:OSL) has attracted investor attention following a series of regulatory, clinical andManufacturingdevelopments during 2026.

Mayne Pharma's shares have been under pressure since a proposed$672 million takeoverby US group Cosette Pharmaceuticals collapsed in late 2025. With litigation ongoing, a strategic review under way and mixedEarnings, the latest share-price recovery has brought renewed attention to the healthcare company.

Key HighlightsWhat happened, and what did not No verifiable company announcement on 3 August 2026 explains a move of that size.Its contents could not be independently verified here, and nothing dated 1 to 3 August appears in the record.The second is mechanics: Mayne was …

A 5 per cent move worth a tenth of a cent That price looks jarring, given Botanix placed AUD 70 million of stock at 30 cents in June 2024, the week its lead product won US approval. Google Finance, TradingView and Botanix's own readers …

A small deal in a business built on beds That takes annualised home-care revenue to roughly AUD 50 million. Against group revenue running at about AUD 1.26 billion on a trailing-twelve-month basis, per Simply Wall St, home care is a low-single-digit share of the …

A rare green tick in a red health sector The contrast is the story. At the same snapshot the S&P/ASX 200 Health Care index was down 0.37 per cent at 26,536.10, one of six of 11 sectors in the red, and the S&P/ASX 200 …

Careteq is a small Australian healthtech company that has undergone a significant reset. Once associated with aged-care andAssistive Technology, it repositioned toward clinical medication management, and in 2026 it went further still — selling its main operating business and re-emerging as a much leaner …